Dianthus Therapeutics announced positive Phase II outcomes for its selective complement inhibitor in patients with generalized myasthenia gravis (gMG). The results indicate meeting multiple efficacy endpoints, positioning the candidate for pivotal Phase III trials. The data offer hope for addressing unmet needs in the treatment of this challenging autoimmune neuromuscular disease, highlighting Dianthus's potential in the competitive gMG therapeutic landscape.